Abstract
A patient with early laryngeal cancer who rejected both radiation therapy and surgery was treated with only chemotherapy of UFT combined with CBDCA. UFT (tegafur 300 mg/day) was administered orally and CBDCA was injected intravenously at a dose of 300 mg/body every 1-2 months, 11 times. For over 2 years the patient has demonstrated gradual tumor growth, but has not complained of dyspnea and has worked every day. The chemotherapy has improved his quality of life.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carcinoma, Squamous Cell / drug therapy*
-
Drug Combinations
-
Humans
-
Infusions, Intravenous
-
Laryngeal Neoplasms / drug therapy*
-
Male
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use*
-
Uracil / administration & dosage
-
Uracil / therapeutic use*
Substances
-
Antineoplastic Agents
-
Drug Combinations
-
UFT(R) drug
-
Tegafur
-
Uracil
-
Carboplatin